Tyrosine kinase inhibitors in cancer therapy

Clinical Biochemistry
Srinivasan Madhusudan, Trivadi S Ganesan

Abstract

Cancer is the second leading cause of death in the western world. Despite advances in diagnosis and treatment, overall survival of patients remains poor. Scientific advances in recent years have enhanced our understanding of the biology of cancer. Human protein tyrosine kinases (PTKs) play a central role in human carcinogenesis and have emerged as the promising new targets. Several approaches to inhibit tyrosine kinase have been developed. These agents have shown impressive anticancer effects in preclinical studies and are emerging as promising agents in the clinic. The remarkable success of BCR-ABL tyrosine kinase inhibitor imatinib (STI571) in the treatment of chronic myeloid leukaemia has particularly stimulated intense research in this field. At least 30 inhibitors are in various stages of clinical development in cancer, and about 120 clinical trials are ongoing worldwide. In this review, we focus on the role of tyrosine kinases in cancer and the development of specific small molecule inhibitors for therapy. We also provide a critical analysis of the current data on tyrosine kinase inhibitors and highlight areas for future research. Issues with regards to the design of clinical trials with such agents are also discussed. In...Continue Reading

References

Aug 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A K TandonW L McGuire
Aug 1, 1981·Naunyn-Schmiedeberg's Archives of Pharmacology·H GlossmannE Eigenbrodt
Oct 1, 1995·Seminars in Cancer Biology·J R Murphy, J C vanderSpek
Apr 1, 1997·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·T UekiE Okamoto
Feb 1, 1997·European Journal of Obstetrics, Gynecology, and Reproductive Biology·H Meden, W Kuhn
May 29, 1998·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·T Hunter
Sep 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·D W FryE M Dobrusin
Nov 10, 1998·Critical Reviews in Eukaryotic Gene Expression·R A FarahE S Vitetta
Jan 29, 1999·Journal of the National Cancer Institute·P le CoutreC Gambacorti-Passerini
Apr 29, 1999·The New England Journal of Medicine·C L Sawyers
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C Eng
Oct 6, 1999·Current Opinion in Immunology·P J Hudson
Nov 5, 1999·Advances in Cancer Research·A Wells
Nov 1, 2000·Cell·J Schlessinger
Dec 15, 2000·Oncogene·D R RobinsonS F Lin
Dec 15, 2000·Oncogene·F A Al-Obeidi, K S Lam
Dec 21, 2000·Trends in Pharmacological Sciences·M SusvaJ Green
Apr 3, 2001·Trends in Pharmacological Sciences·M J Cross, L Claesson-Welsh
Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Apr 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D W AndrewsR D Aiken
May 18, 2001·Nature·P Blume-Jensen, T Hunter
Jul 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M HidalgoE K Rowinsky
Oct 13, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R I NicholsonM E Harper
Oct 19, 2001·Oncogene·J DuysterS W Morris
Oct 20, 2001·Critical Reviews in Immunology·M L DisisK Schiffman
Nov 14, 2001·Seminars in Oncology·W J SlichenmyerD W Fry
Dec 1, 2001·Expert Opinion on Biological Therapy·J Hasan, G C Jayson
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joan AlbanellJose Baselga
Feb 14, 2002·Trends in Molecular Medicine·Esther ZwickAxel Ullrich
Mar 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bart C KuenenGiuseppe Giaccone

❮ Previous
Next ❯

Citations

Dec 17, 2008·Pediatric Radiology·Peter C Adamson
May 15, 2013·Computers in Biology and Medicine·Natarajan SathishkumarDeok-Chun Yang
Mar 1, 2005·Photodiagnosis and Photodynamic Therapy·Ana P CastanoMichael R Hamblin
Nov 15, 2006·Annals of Surgical Oncology·Neeltje SteeghsHans Gelderblom
May 24, 2011·World Journal of Clinical Oncology·Fleur BroekmanGodefridus J Peters
Oct 12, 2007·Future Oncology·Kiven E Lukong, Stéphane Richard
Nov 12, 2013·Antioxidants & Redox Signaling·Jie Li, Qishen Pang
Jul 15, 2015·Journal of Enzyme Inhibition and Medicinal Chemistry·Amer M AlanaziAdel S El-Azab
Jul 25, 2015·Expert Opinion on Investigational Drugs·Claudia MarchettiPierluigi Benedetti Panici
Jul 3, 2013·Expert Opinion on Investigational Drugs·Matteo MorottiSimone Ferrero
Oct 24, 2007·Cancer Investigation·Jeffrey M Skolnik, Peter C Adamson
May 25, 2007·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·M IshizukaS Fujita
Jun 19, 2013·Critical Reviews in Oncology/hematology·Girolamo RanieriRaffaele Luigi Sciorsci
May 23, 2012·Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons·Zachary S PeacockLarry L Cunningham
Nov 25, 2011·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Fenlai TanYinxiang Wang
Mar 17, 2010·Cancer Treatment Reviews·John Araujo, Christopher Logothetis
Sep 8, 2009·Topics in Companion Animal Medicine·Cheryl A London
Nov 13, 2015·Cancer Treatment Reviews·C MarchettiP Benedetti Panici
Jan 14, 2009·Journal of Molecular Graphics & Modelling·Qing-Qing XieSheng-Yong Yang
Jun 14, 2008·International Journal of Pharmaceutics·M E M DolmanR J Kok
Oct 24, 2007·The Veterinary Clinics of North America. Small Animal Practice·Cheryl A London
Feb 10, 2007·Biochemical and Biophysical Research Communications·Ralf KrügerWolf D Lehmann
Dec 1, 2004·Veterinary and Comparative Oncology·C London
Aug 14, 2012·Veterinary and Comparative Oncology·S Bavcar, D J Argyle
Jan 22, 2013·Veterinary Dermatology·Cheryl A London
Jul 18, 2006·International Journal for Parasitology·Jürgen KnoblochChristoph G Grevelding
Dec 27, 2005·Trends in Pharmacological Sciences·Franz F HeftiAlun M Davies
Jul 1, 2005·Seminars in Oncology·Nicholas J VogelzangLuciano Mutti
Mar 7, 2009·The American Journal of Pathology·Maria Letizia TaddeiPaola Chiarugi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis